340B drug discounts are drifting from patients to profit, and reform is now on the table
medicalxpress - The 340B Drug Pricing Program must be reformed to better patient health and disincentivize institutional profit-seeking behaviors, says the American College of Physicians (ACP). In a new policy, "Reforming 340B to Promote Program Integrity and Better Serv…
AI Summary: The 340B drug-discount program is under renewed scrutiny after analyses and advocacy groups argue discounts intended to help patients are instead boosting institutional margins. Hospitals, provider groups and the AHA are contesting HRSA proposals and court rulings, sparking policy debates and potential regulatory fixes to curb markups and steer savings back to vulnerable patients.
RFK Jr. says China is 'eating our lunch' in biotech advances
Zachary Brennan / endpoints - China is "eating our lunch" on new drug approvals and clinical trial starts, HHS Secretary Robert F. Kennedy Jr. told Congress Tuesday, while praising the FDA's actions so far. "We are losing scientists, we're losing ...
AI Summary: Robert F. Kennedy Jr. publicly criticized U.S. biotech competitiveness—singling out China as gaining ground—and declined to fully endorse the new CDC vaccine director, blending industry critique with public‑health ambivalence. His comments underscore tensions between political positioning and health policy messaging while rattling stakeholders who prefer facts over theatrical proclamations.
- Kennedy defensive in hearings, balancing White House and base (4)
- Kennedy hesitates on CDC director, vaccine reports spark debate (5)
- On Pharma frontlines: Kennedy warns China is eating our lunch (3)
- All Other Stories